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AbstrACt
Objective To assess the safety and feasibility of small 
volume plasma exchange (SVPE) for patients with Guillain-
Barré syndrome (GBS).
Design Non-randomised, single-arm, interventional trial.
setting National Institute of Neurosciences and Hospital, 
Dhaka, Bangladesh.
Participants Twenty adult (>18 years) patients with GBS 
presented within 2 weeks of onset of weakness who were 
unable to walk unaided for more than 10 m.
Interventions SVPE involves blood cell sedimentation in a 
blood bag and removal of supernatant plasma after blood 
cells are retransfused. This procedure was repeated three 
to six times a day, for eight consecutive days. Fresh frozen 
plasma (FFP) and normal saline were used as replacement 
fluid.
Outcome measures Serious adverse events (SAEs) were 
defined as severe sepsis and deep venous thrombosis related 
to the central venous catheter (CVC) used during SVPE. SVPE 
was considered safe if less than 5/20 patients experienced 
an SAE, and feasible if 8 L plasma could be removed within 8 
days in at least 15/20 patients.
results Median patient age 33 years (IQR 23–46; range 
18–55); 13 (65%) were male. Median Medical Research 
Council (MRC) sum score was 20 (IQR 0–29; range 0–36); 
three (15%) patients required mechanical ventilation. One 
patient developed SAE (severe sepsis, possibly related to 
CVC). The median plasma volume exchanged was 140 mL/
kg (range 110–175) and removal of 8 L plasma was possible 
in 15 (75%) patients. Patients received a median 1 g/kg IgG 
via FFP although a substantial proportion of IgG was probably 
removed again by the SVPE sessions. GBS disability score 
improved by at least one grade in 14 (70%) patients 4 weeks 
after SVPE started. No patients died.
Conclusion SVPE seems a safe and feasible alternative 
treatment to standard plasma exchange (PE) or intravenous 
immunoglobulin (IVIg) for GBS; further studies of clinical 
efficacy in low-income and middle-income countries are 
warranted.
trial registration number NCT02780570.
IntrODuCtIOn  
Guillain-Barré syndrome (GBS) is an acute 
immune-mediated polyradiculoneuropathy 
with a yearly incidence of 1.2–2.3 cases per 
100 000 per year.1 GBS is characterised by 
rapidly progressive limb weakness and, in a 
proportion of cases, respiratory failure (25%) 
or severe autonomic dysfunction (10%). 
Plasma exchange (PE) was the first treat-
ment proven to be effective for GBS, if given 
within 4 weeks of the onset of weakness.2–11 
Conventionally for patients with GBS, three 
to five plasma exchange (PE) sessions are 
done in alternate days within a span of 7–14 
days targeting a PE rate of 120–200 mL/kg 
(40–50 mL/kg/day).7 Later studies showed 
treatment with intravenous immunoglob-
ulin (IVIg) (0.4 g/kg per day for 5 days) has 
a similar efficacy as PE in patients with GBS 
who are unable to walk, if started within 2 
weeks of the onset of weakness.12 13 
Unfortunately, most patients in low-in-
come countries cannot afford expensive 
strengths and limitations of this study
 ► The strength of this study underlies the novel and 
simple technique of small volume plasma exchange 
(SVPE), which is much less expensive than conven-
tional immunotherapies (plasma exchange (PE) and 
intravenous immunoglobulin (IVIg)).
 ► SVPE is corroborated as safe and feasible for the 
first time in a prospective and standardised cohort 
of patients with Guillain-Barré syndrome (GBS).
 ► The intrinsic limitations of this study are its non-ran-
domised, single-arm nature, which is conducted in a 
single centre with a limited sample size of patients 
with GBS. The volume exchanged was at the lower 
range compared with previous PE studies conducted 
in GBS.
 ► Clinical efficacy of SVPE on patients with GBS was 
a secondary endpoint assessment and therefore 
deserves a randomised controlled trial in future to 
assess the clinical efficacy of SVPE for the patients 
with GBS.
 o
n
 13 M
ay 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-022862 on 17 August 2018. Downloaded from 
2 Islam B, et al. BMJ Open 2018;8:e022862. doi:10.1136/bmjopen-2018-022862
Open access 
treatment with either PE or IVIg.14 In Bangladesh, a 
full course of IVIg for a 60 kg adult costs approximately 
US$12 000–US$16 000 and treatment with conventional 
PE for 5 days costs approximately US$4500–US$5000. 
The mean income in Bangladesh was US$4 per day in 
2016 (World Bank and Bangladesh Bureau of Statistics 
2016); IVIg and PE cost the equivalent of 4,000 and 1250 
mean income days, respectively. At present, the majority 
(92%) of patients with GBS in Bangladesh receive 
supportive care only.14 In addition, mobile PE equip-
ment is not available in Bangladesh; therefore, patients 
admitted to the intensive care unit (ICU) cannot receive 
PE. We previously reported the mortality rates for GBS 
in Bangladesh range from 12% to 14% and observed 
29% of patients with GBS in Bangladesh are unable to 
walk at 6 months after onset; these poor outcomes are 
undoubtedly due to the low rates of specific treatment 
with PE or IVIg.15 16
Small volume plasma exchange (SVPE) may represent 
a cheap, effective alternative treatment for GBS. SVPE is 
based on the same principle as conventional PE (selective 
removal of plasma) but uses a novel, simple technique 
with much lower costs (approximately US$500). The 
current non-randomised trial was designed to investi-
gate the safety and feasibility of SVPE in 20 patients with 
GBS admitted to the National Institute of Neurosciences 
Hospital (NINS) in Dhaka, Bangladesh.
MethODs/DesIgn
study design
For this non-randomised, single-arm, interventional 
safety and feasibility trial, 20 adult patients with GBS were 
enrolled between March 2016 and December 2016 for 
SVPE at the NINS, Dhaka, Bangladesh. A detailed study 
protocol was published previously and includes defini-
tions of all variables used in this study.17
Four to six daily sessions of whole blood sedimentation 
and removal of supernatant plasma after retransfusion 
of the sedimented blood cells were planned for the 20 
patients with GBS, with a target of removing an overall 
volume of at least 8 L of plasma over a total of 8 days17 
(see online supplementary video for SVPE procedure).
Patients with GBS were monitored according to a 
standard protocol throughout the course of SVPE until 
the second day after withdrawal of the central venous 
catheter (CVC) in order to assess predefined measures 
of safety and feasibility and followed up for 6 months to 
assess neurological outcome. and The protocol is regis-
tered at  ClinicalTrials. gov (NCT02780570).17
Patient and public involvement
Patients and or public were not involved either in the 
development of the research question, study design and 
outcome measure or recruitment to and conduct of the 
study.
Inclusion and exclusion criteria for patients with gbs
Patients aged ≥18 years old fulfilling the diagnostic 
criteria for GBS of the National Institute of Neurolog-
ical and Communicative Disorders and Stroke18 were 
enrolled, provided they were unable to walk unaided 
for more than 10 m (GBS disability score ≥3), presented 
within 2 weeks of the onset of weakness and were unable 
to afford standard treatment with IVIg or PE. Patients 
with concomitant severe or terminal illnesses, evidence 
of healthcare-associated infection (HAI) on admission 
(except for aspiration pneumonia), a previous history of 
severe allergic reactions to properly matched blood prod-
ucts and pregnant women were excluded from the study.
Control cohort
To compare the safety of SVPE in patients with GBS in 
the context of the background risk of central line-asso-
ciated blood stream infection (CLABSI) at our institu-
tion, we prospectively assessed the incidence of CLABSI 
in a hospital control group of 24 adult patients without 
GBS receiving neurocritical care. Hospital controls were 
eligible based on the following characteristics: ≥18 years 
old, a neurological diagnosis other than GBS and a CVC 
placed for >2 and ≤8 calendar days after admission to the 
same intensive care unit (ICU) or high dependency unit 
(HDU) unit as the SVPE-treated patients. Patients with 
an HAI (except aspiration pneumonia) and pregnant 
women were excluded from the control group.
Primary and secondary outcome measures
The primary outcome measures of safety were the number 
of patients with GBS treated with SVPE who developed 
either severe sepsis or septic shock due to CLABSI19 and 
the occurrence of venous thrombosis in the limb where 
the CVC was placed. The primary outcome measure of 
feasibility was the ability to remove at least 8 L of plasma 
over 8 days.
The secondary outcome measures of the safety of SVPE 
were the relative risk of CLABSI due to SVPE (compared 
with CLABSI in the hospital control group without GBS), 
haemodynamic instability during the SVPE procedure 
and development of anaemia (haemoglobin, (Hb) <8 g/
dL) or any catheter-related haemorrhage requiring a 
blood transfusion.
The secondary outcome measure of feasibility of SVPE 
was the rate of CVC occlusion during the SVPE proce-
dure. In addition, neurological outcome was assessed 
using the GBS disability score,20 Medical Research 
Council (MRC) sum score,21 Overall Neuropathy Limita-
tion Scale (ONLS)22 and Rasch-built Overall Disability 
Scale (R-ODS)23 at 1st, 2nd, 3rd and 6th months from the 
start of SVPE.
Procedure safety documentation and cost of sVPe
Strict aseptic procedures were followed to prevent 
CLABSI.24–26 SVPE was documented in terms of the dura-
tion and amount of plasma removed in each session, 
and the type and volume of replacement fluid and fresh 
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frozen plasma (FFP) used. Throughout the procedure, 
the haemodynamic, haematological, biochemical, coagu-
lation and infection profiles of the SVPE-treated patients 
were monitored according to the protocol.17 Screening 
for hepatitis B and C viruses, HIV and syphilis were 
performed as patient baseline assessments, and also on 
donor FFP before administration. CLABSI, primary and 
secondary bloodstream infections,19 catheter-associated 
urinary tract infection (CAUTI),27 ventilator-associated 
pneumonia (VAP)28 and other HAI29 30 were documented 
in the SVPE-treated patients with GBS and the hospital 
control group. Expenditure for the full course of SVPE 
will be approximately US$500 (fresh frozen plasma (FFP 
(24 bags)=US$240, blood bag and saline sets: US$40, 
low-molecular-weight heparin: US$110, routine investi-
gation: US$50, saline: US$10, CV catheter: US$40 =total 
US$490).
sample size
This safety and feasibility study enrolled 20 patients 
with GBS for SVPE. We could not perform a formal 
power calculation for this safety and feasibility study. 
The sample size was based on previous pilot studies 
conducted in GBS.31 32 The baseline rate of CLABSI was 
measured in the hospital control group of 24 patients 
without GBS admitted to the same study facility who 
required a CVC for at least 8 days during the study 
period.
stopping rules for the trial based on safety and feasibility
Decision to stop the SVPE trial was designated using a 
Bayesian approach.33–35 Accordingly, a predictive success 
rate of 75% was predefined for the SVPE procedure. If 
more than 5 of 20 patients experienced a serious adverse 
event (SAE), or if it appeared impossible to remove at 
least 8 L of plasma over 8 days in at least 15 of 20 patients, 
the procedure was considered unsafe or not feasible.
statistical analysis
The rates of HAIs (CLABSI, VAP and CAUTI) per 1000 
device days were calculated by dividing the number of 
each HAI during the study period by the number of 
device days and multiplying the result by 1000. The infec-
tion safety profile for SVPE was assessed by calculating 
the standardised infection ratio (SIR) to define the risk 
of HAIs in patients with GBS treated with SVPE. The 
SIR was calculated by dividing the number of observed 
HAI by the number of HAI predicted (ie, the infection 
rate in the control group). The predicted HAI rate was 
calculated using the rates of HAI in the hospital control 
group of patients without GBS during the study period. 
Percentage values were compared using the χ2 test or 
Fisher’s exact test (two tailed) and median values, the 
Mann-Whitney U test using SPSS V.22.0 (IBM SPSS). 
Analyses were performed on an intention-to-treat basis. 
All p values reported are two sided; p<0.05 was consid-
ered significant.
results
Patients and hospital controls
The demographic and clinical characteristics of the 20 
patients with GBS are given in table 1. The median age 
of the patients with GBS was 33 years (range 18–55); 
median body weight was 60 kg (IQR 55–65 kg; range 
50–72 kg) and 13 (65%) patients were male (figure 1). 
On admission and before the start of SVPE, all 20 
patients with GBS were unable to walk independently 
(GBS disability score, 4). One patient required mechan-
ical ventilation from the second day after the onset 
of weakness; SVPE was started on the fourth day of 
mechanical ventilation (patient 9, figure 1). Two of the 
19 patients who did not require mechanical ventilation 
at the start of the study required mechanical ventilation 
on the second day after initiation of SVPE (patients 11 
and 19, 11 and 2 days after the onset of weakness, respec-
tively; figure 1). The median MRC sum score for the 
limb muscles in all 20 patients was 20 (IQR 0–29; range 
Table 1 Demographic and clinical characteristics of the 
20 patients with GBS included in this small volume plasma 
exchange study at entry
Characteristic Values
Demography
  Sex (male to female ratio) 13:7 (1.85)
  Age (years)* 33 (18–55)
Body weight (kg)* 60 (50–72)
Antecedent events† (total) 18 (90%)
  Diarrhoea 10 (50%)
  Respiratory infection 5 (25%)
  Fever 3 (15%)
Days from antecedent events to weakness* 7 (3–30)
Days between onset of weakness and 
admission*
7 (2–12)
Neurological deficits at entry
  Weakness in arms and legs 20 (100%)
  Cranial nerve deficits 12 (60%)
  Decreased deep tendon reflexes 20 (100%)
  Sensory involvement 5 (25%)
  GBS disability score‡
   4 19 (95%) 
   5 1 (5%)
  Severity of weakness (MRC sum score)* 20 (0–29)
  Autonomic dysfunction 11 (55%)
*Median (range). 
†Symptoms of an infection in the 4 weeks preceding the onset of 
weakness.
‡GBS disability score (0–6)=0: healthy state; 1: minor symptoms 
and capable of running; 2: able to walk 10 m or more without 
assistance but unable to run; 3: able to walk 10 m across an open 
space with help; 4: bedridden or chairbound ; 5: requiring assisted 
ventilation for at least part of the day; 6: dead.
GBS, Guillain-Barré syndrome; MRC, Medical Research Council.
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0–36; figure 1). Symptoms of a preceding infection in 
the 4 weeks before the onset of weakness were present 
in 18 (90%) patients with GBS, of whom 10 (50%) had 
diarrhoea. Median duration from admission to start of 
SVPE was 2 days (IQR 2–3 days; range 0–7 days). Median 
duration to nadir from the onset of weakness was 5 days 
(range 1–13 days). Electrodiagnostic nerve conduc-
tion studies (NCS) indicated 15 (75%) patients had an 
axonal subtype and 5 (25%) patients had a demyelin-
ating subtype of GBS. Median duration from onset of 
weakness to NCS examination was 10 days (range 4–16 
days). All patients had albuminocytological dissocia-
tion in cerebrospinal fluid (CSF) analysis (CSF protein 
level >45 mg/dL in combination of CSF cell count <50 
per μL); median CSF protein was 166 mg/dL (range 
117–253 mg/dL). Median duration from onset of weak-
ness to CSF examination was 11 days (range 4–17 days).
Median age of the 24 hospital control patients 
without GBS was 44 years (IQR 25–57; range 18–74); 10 
(42%) were male. Age and gender distribution were not 
significantly different compared with the 20 patients 
with GBS (p=0.2155, p=0.1434, respectively). The diag-
noses for these 24 patients were: brain tumour (n=5), 
transverse myelitis (n=5), head trauma after road traffic 
accident (n=3), viral meningoencephalitis (n=2), myas-
thenia gravis (n=2), compressive cervical myelopathy 
(n=2), cerebrovascular accident (n=2), motor neuron 
disease (n=1), electrolyte imbalance (n=1) and status 
epilepticus (n=1).
Primary endpoints
One patient with GBS treated with SVPE developed 
severe sepsis, possibly due to SVPE-related CLABSI 
(SVPE window-period blood culture revealed meth-
icillin-resistant Staphylococcus aureus). This patient 
required intravenous fluid, noradrenalin infusion 
and intravenous antibiotics, but eventually improved 
(patient 11, figure 1). This patient also had signs and 
symptoms suggestive of aspiration pneumonia and 
VAP; Streptococcus spp. was isolated from pulmonary 
aspirates. Further laboratory results revealed dyse-
lectrolytaemia, anaemia and hypoalbuminaemia. No 
patients experienced deep vein thrombosis due to the 
CVC for SVPE. Fifteen (75%) of the 20 patients met 
the primary endpoint of feasibility, defined as the ability 
to remove at least 8 L of plasma in 8 days. The median 
volume of plasma removed was 8.5 L (IQR 7.9–8.8 L; 
range 6.3–9.6 L; figure 1). The median PE rate was 
140 mL/kg bodyweight (IQR 125–155 mL/kg; range 
110–175 mL/kg) over 8 days and 16 (80%) patients had 
a PE rate >120 mL/kg (table 2).
secondary endpoints
Infections among SVPE-treated patients with GBS and hospital 
controls
Among the 20 patients with GBS treated with SVPE, six 
(30%) had fever during SVPE (figure 1, online supple-
mentary figure 1), including two (10%) patients with 
leucocytosis who were diagnosed with HAI (VAP and 
Figure 1 Feasibility of SVPE and associated complications for the 20 individual patients with GBS. AMeasured in litres. B, 
central line-associated blood stream infection; C, urinary catheterisation; CVC, central venous catheter; GBS, Guillain-Barré 
syndrome; HAI, hospital-acquired infection; M, onset of mechanical ventilation; MRC, Medical Research Council; SVPE: small 
volume plasma exchange; U, catheter-associated urinary tract infection; V, ventilator-associated pneumonia, , spell of 
hypotension (systolic blood pressure <90 mm Hg); , CVC insertion site bleeding; , hypersensitivity to fresh frozen plasma, 
shaded squares: fever due to bacterial infection, dotted squares: fever due to suspected viral infection. 
 o
n
 13 M
ay 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-022862 on 17 August 2018. Downloaded from 
5Islam B, et al. BMJ Open 2018;8:e022862. doi:10.1136/bmjopen-2018-022862
Open access
CAUTI in one patient; VAP in one patient). In three out 
of four (20%) patients with fever without leucocytosis, 
fever subsided within 2–3 days without antimicrobial 
therapy (figure 1). The remaining patient with fever 
without leucocytosis had microbiological evidence of 
both CLABSI and VAP (patient 11, figure 1). In all other 
14 patients with GBS, no fever was documented during 
the course of SVPE until the 10th day of SVPE (second 
day after removal of the CVC for SVPE). Five of these 14 
patients had leucocytosis, but no site-specific HAI could 
be detected. However, one of the nine patients without 
fever but leucocytosis fulfilled the criteria for CAUTI 
(patient 12, figure 1). All three patients who required 
mechanical ventilation subsequently developed VAP; 
2 of the 13 patients who required a urinary catheter 
developed a CAUTI (patient 11, figure 1). No patients 
died during the 6 months follow-up.
All 24 hospital control patients without GBS required 
mechanical ventilation and an indwelling urinary cath-
eter. Of these patients, 22 (92%) patients had fever, of 
whom 15 (63%) had leucocytosis; a diagnosis of a specific 
HAI could be made 14 of these 15 patients (CLABSI 
in 2, CAUTI in 1, VAP in 11) and 4 (17%) fulfilled the 
criteria for severe sepsis (online supplementary figure 
1). Seven (29%) of the 24 hospital control patients had 
fever without leucocytosis. In two of these seven patients, 
a specific HAI was diagnosed (CAUTI and VAP in one, 
and VAP in one). In two hospital control patients, no 
fever was documented until day 10 after first placement of 
the CVC, but leucocytosis was present and no site-specific 
HAI could be detected (online supplementary figure 1).
The rates of CLABSI, CAUTI and VAP per 1000 device 
days in the SVPE-treated patients with GBS were 6.25, 
19.2 and 40 compared with 10.4, 10.4 and 67.7 for the 
hospital control patients without GBS, respectively. The 
relative risks of CLABSI, CAUTI and VAP associated 
with SVPE were 0.6, 1.2 and 1.8, respectively, compared 
with hospital control patients. The rates of CLABSI, 
CAUTI and VAP were comparable between SVPE-treated 
patients with GBS and hospital control patients (p>0.05). 
Table 2 Treatment characteristics and complications 
associated with SVPE in the 20 patients with GBS
Characteristic/complication Values
Treatment characteristics
  No of sessions of SVPE per patient* 30 (24–42)
  Volume of plasma removed per 
patient*
8.4 (6.3–9.6)
  Plasma exchange rate (mL/kg)* 140 (110–175)
  Time between hospital admission 
and SVPE (days)*
8 (5–10)
  Time between onset of weakness 
and start of SVPE (days)*
8 (5–10)
  Need to stop SVPE due to poor 
haemodynamic tolerance
0/20 (0%)
  Need for blood transfusion for 
anaemia
1/20 (5%)
  Reduction of anticoagulant drug 
dose for bleeding
3/20 (15%)
  Temporary withdrawal of antiplatelet 
drug for bleeding
4/20 (20%)
  Increased anticoagulant drug dose 
to continue SVPE
1/20 (5%)
  CVC blockade/replacement 0/20 (0%)
Complications during SVPE
  Infection
   Leucocytosis 7/20 (35%)
   CLABSI† 6.25
   VAP† 136.4
   CAUTI† 40
   Severe sepsis 1/20 (5%)
   Antimicrobial agents used 6/20 (30%)
  Bleeding and coagulation
   Bleeding from CVC insertion site 10/20 (50%)
   Bleeding from mucosal area 3/20 (15%)
   Prolonged BT (BT >10 min) 0/20 (0%)
   Prolonged CT (CT >15 min) 0/20 (0%)
   Prolonged PT (PT >14 s)* 6/20 (30%) (15–19 s)
   Prolonged aPTT (aPTT >40 s)* 3/20 (15%) (51–240 s)
  Other complications
   Saline responsive hypotension 10/20 (50%)
   Anaemia (Hb <8 g/L) 2/20 (10%)
  Thrombocytopaenia
  (Platelet count < 1.5 x10^9/L)*
6/20 (30%)
(0.79-1.3 x10^9/L)
  Jaundice (serum
  bilirubin >1.2 mg/dL)
0/20 (0%)
  Renal impairment (serum
  creatinine >1.2 mg/dL)
0/20 (0%)
  Hyponatraemia (serum
  Na+ <135 mEq/L)*
1/20 (5%) (126 mEq/L)
  Hypocalaemia
  (serum K+ <3.5 mEq/L)*
3/20 (15%) (2.6–3.2 mEq/L)
  Hypoalbuminaemia (serum
  albumin >35 gm/L)*
4/20 (20%) (26–32 gm/L)
Continued
Characteristic/complication Values
  Hypocalcaemia
  (serum Ca+ <2.2 mmol/L)*
3/20 (15%) (1.89–1.98 
mmol/L)
  Hypomagnesaemia
  (serum Mg+ <75 mEq/L)*
1/20 (5%) (73 mEq/L)
  Hypersensitivity/transfusion
  reaction to FFP
4/20 (20%)
*Exact value or range, which is appropriate.
†Rate per 1000 device days.
APTT, activated partial thromboplastin time; BT, bleeding time; 
CT, clotting time; CAUTI, catheter-associated urinary tract 
infection; CLABSI, central line-associated bloodstream infection; 
CVC, central venous catheter; FFP, fresh frozen plasma; GBS, 
Guillain-Barré syndrome; Hb, haemoglobin; PT, prothrombin time; 
SVPE, small volume plasma exchange; VAP, ventilator-associated 
pneumonia. 
Table 2 Continued 
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Antimicrobial agents were used more frequently in the 
hospital control patients (p<0.0001; figure 2). The SIRs 
for CLABSI, CAUTI and VAP for SVPE-treated patients 
with GBS were 0.6, 1.8 and 1.9, respectively.
Other secondary endpoints
Ten (50%) of the 20 patients treated with SVPE experi-
enced transient hypotension during SVPE, which was 
corrected by infusion of 200–300 mL crystalloid saline 
(figure 1). Minor bleeding through the CVC insertion 
site (excluding at the time of insertion) was observed in 
10 of  20 patients (50%; figure 1); these bleeds required a 
pressure pack. Reduction of the anticoagulant dose along 
with a pressure pack was required in 3 of 20 patients, 
who all had a prolonged prothrombin time (PT). Three 
patients had single episode of haemorrhage through the 
urinary catheter: one was diagnosed with a CAUTI with 
normal coagulation profile, one had a prolonged PT, the 
other had sterile haematuria with normal PT. Overall, PT 
and activated partial thromboplastin time (aPTT) were 
prolonged in 4 of 20 patients and only PT was prolonged 
in 2 of 20 patients. Clotting time (CT) and bleeding time 
were not prolonged in any patient. One patient developed 
anaemia (Hb, 8 g/dL) at the end of SVPE; this patient 
also had severe sepsis and required one unit of blood 
transfusion (patient 11, figure 1). CVC blockages were 
not observed in any SVPE-treated patients with GBS. One 
patient with increased clotting tendency who required 
an increased dose of low-molecular-weight heparin had 
shortened CT(<50% of upper limit of normal), though 
PT was normal (patient 10, figure 1).
The neurological outcomes of the SVPE-treated patients 
with GBS at 6 months in terms of neurological scores 
are given in table 3. Median time to recover the ability 
to walk unaided was 4 weeks (figure 3). Fourteen (70%) 
of the 20 patients had an improvement in GBS disability 
score of one or more grades at 4 weeks after the onset of 
SVPE. At 1 month, 12 patients (60%) were able to walk 
unaided, 2 patients (10%) were able to walk aided and 6 
(30%) patients were bedbound, of whom 3 still required 
Figure 2 Hospital-acquired infections and use of antibiotics 
in the 20 patients with GBS receiving SVPE compared 
with the 24 hospital control patients without GBS treated 
in the same ICU and HDU with a CVC who did not receive 
SVPE.  SVPE (n=20): 20 patients with GBS aged ≥18 years 
old who were bedbound (GBS disability score ≥4) received 
SVPE within 2 weeks of the onset of weakness.  Non-SVPE 
(n=24): 24 patients aged ≥18 years old with a diagnosis other 
than GBS who required a CVC for >2 to ≤8 calendar days 
after admission to the same ICU and HDU units in the same 
period as the patients with GBS received SVPE. *P<0.0001. 
CLABSI, central line-associated blood stream infection; 
CAUTI, catheter-associated urinary tract infection; CVC, 
central venous catheter; GBS, Guillain-Barré syndrome; ICU, 
intensive care unit; SVPE, small volume plasma exchange; 
VAP, ventilator-associated pneumonia. 
Table 3 Neurological outcomes of the 20 patients with GBS after SVPE
Clinical outcome 1 month 2 months 3 months 6 months
Cranial nerve involvement 7/20 (35%) 6/20 (30%) 4/20 (20%) 2/20 (10%)
Autonomic involvement 3/20 (15%) 3/20 (15%) 0/20 (0%) 0/20 (0%)
Sensory dysfunction 1/20 (5%) 1/20 (5%) 1/20 (5%) 1/20 (5%)
GBS disability score* 0=0 0=1 0=1 0=2
1=3 1=6 1=7 1=7
2=9 2=6 2=6 2=5
3=2 3=1 3=1 3=3
4=3 4=5 4=5 4=3
5=3 5=1 5=0 5=0
MRC sum score† 47 (0–60) 49 (0–60) 53 (6–60) 58 (22–60)
ONLS 4 (1–12) 3 (0–12) 3 (0–12) 2 (0–10)
R-ODS 26 (0–41) 33 (0–45) 37 (0–45) 38 (0–46)
*GBS disability score (0–6)=0: healthy state, 1: minor symptoms and capable of running, 2: able to walk 10 m or more without assistance but 
unable to run, 3: able to walk 10 m across an open space with help, 4: bedridden or chairbound , 5: requiring assisted ventilation for at least 
part of the day, 6: dead.
†Median (range).
GBS, Guillain-Barré syndrome; MRC, Medical Research Council; ONLS, Overall Neuropathy Limitation Scale22; R-ODS, Rash-built Overall 
Disability Score23; SVPE, small volume plasma exchange.
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mechanical ventilation. At 3 months, 14 (70%) patients 
were able to walk unaided, 1 (5%) could walk with aid 
and 5 (25%) patients were bedbound. At 6 months, 14 
(70%) patients were able to walk unaided, 3 (5%) could 
walk with aid and 3 (15%) remained bedbound (table 3).
Other relevant clinical and laboratory findings
Allergic/transfusion reaction to FFP was observed in four 
patients with GBS treated with SVPE (figure 1). These 
transfusion reactions presented as an itchy erythematous 
skin rash (three patients), fever (two patients), hypoten-
sion (one patient) following transfusion of FFP; all of 
these reactions were managed with oral antihistamine 
(and intravenous saline in one patient) without further 
complications.
The other documented haematological and biochem-
ical abnormalities were hypoalbuminaemia (n=4), throm-
bocytopaenia (n=6), hyponatraemia (n=1), hypocalaemia 
(n=3), hypomagnesaemia (n=1), hypocalcaemia (n=3); 
(table 2).
Immunoglobulin dosage admitted by FFP
During SVPE the median volume of FFP administered 
per patient with GBS as replacement fluid was 6000 mL 
(range 5000–6000 mL). Considering the normal plasma 
IgG level of 11.20 mg/mL (range 6.9 –17.6 mg),36 SVPE-
treated patients with GBS received IgG dose of median 
0.9 g/kg (range 0.6–1.3 g/kg).
DIsCussIOn
Principal findings
This study suggests SVPE may represent a safe and feasible 
alternative to conventional PE for patients with severe 
GBS in resource-limited settings. Of the 20 patients in this 
study, one (5%) experienced an SAE (severe sepsis due to 
probable CLABSI). The rate of SAE was not significantly 
higher than the hospital control group without GBS with a 
CVC, and no patients had a CVC-related thromboembolic 
event in patients with SVPE. We were able to remove the 
prespecified target volume (8 L) of plasma as the target 
primary endpoint of feasibility in 15/20 (75%) patients 
with GBS. Median PE volume and rate during SVPE were 
8.4 L and 140 mL/kg, respectively. Minor adverse effects 
included transient hypotension during SVPE in 50% 
(10/20), minor haemorrhage from CVC insertion site in 
50% (10/20), transfusion reaction to FFP in 20% (4/20), 
and hypoalbuminaemia, anaemia and electrolyte imbal-
ance in 20% (4/20) of patients. An improvement of at 
least one grade on the GBS disability score was observed 
for 14/20 (70%) patients at 4 weeks after the initiation of 
SVPE. No patients died.
Comparison with baseline hospital control patients and 
standard/modified Pe
With respect to HAIs, no significant differences were 
observed in the frequency of CLABSI, severe sepsis, VAP 
or CAUTI between the SVPE-treated patients with GBS 
and 24 hospital control patients without GBS treated 
using a CVC in the same ICU or HDU (figure 2). However, 
antimicrobial agents were used more frequently, usually 
prophylactically, in the hospital control patients compared 
with the patients with GBS treated with SVPE (p<0.0001; 
figure 2). The probability of detecting micro-organ-
isms in clinical infections may have been reduced due 
to overzealous use of antibiotics in the hospital control 
patients. Early trials of PE in patients with GBS showed 
34% of patients develop severe infections.7 11 Subse-
quently, another large trial documented septicaemia in 
19% of patients.5 However, the rates of CLABSI were not 
reported.
A previous randomised controlled trial (RCT) on GBS 
from the USA showed a beneficial effect with PE rate of 
40–50 mL/kg/session, for three to five sessions in 7–14 
days, which comes to a total PE volume of 120–250 mL/
kg.7 The first French RCT on adult patients with GBS 
showed beneficial effect of four PE sessions (two plasma 
volume (3.5 L) per PE session) over 8 days and in range, 
6–12 L plasma was removed per patient.4 Subsequent 
French RCT with PE dose escalation showed, two PE 
sessions (1.5 plasma volume per PE session) are benefi-
cial in mild to moderate GBS cases but less effective than 
four PE sessions in severe GBS cases and six PE sessions 
are as effective as four PE sessions in severe cases of GBS.5 
In this RCT, the exact total plasma volume exchanged per 
patient was not mentioned, but the authors indicated that 
the rate of PE was 40 mL/kg body weight per PE session. 
As to that a 60–70 kg person should have an exchange of 
2.4–2.8 L per session and the therapeutic range of plasma 
volume to be exchanged would be 5.6–11.2 L mL (two to 
four PE sessions).
During the piloting of the SVPE procedure we assessed 
that removal of 1 L of patient plasma could be feasible in 
Figure 3 Kaplan-Meier estimate (with 95% confidence 
limits) of the cumulative incidence of restoration of 
independent walking ability in patients with Guillain-Barré 
syndrome treated with small volume plasma exchange 
(SVPE).
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a day. Therefore, we defined our target plasma volume of 
8 L to be removed in 8 days. The median total PE volume 
and rate in SVPE was 8.4 L and 140 mL/kg, which is at the 
lower range as compared with both the French and Amer-
ican RCT on PE for adult patients with GBS. We were able 
to remove >120 mL/kg plasma in 80% of patients, which 
should provide a therapeutic effect.37 Notably, the body 
weight of our patients may be lower than that of patients 
in Western countries. In addition, SVPE was complete 
within 8 days, shorter than the usual time required for a 
full session of PE (10–12 days).
Replacement fluid used in SVPE was FFP. We have several 
justifications in favour of using FFP instead of human 
albumin or other available colloidal solutions available 
in Bangladesh. First, FFP is safe in terms of microbiolog-
ical safety since stringent screening for viral and bacterial 
contamination was performed before infusion. Second, 
in contrast to human albumin and colloid solutions, FFP 
contains normal human IgG that could contribute to the 
beneficial immunotherapeutic effect in GBS. FFP was 
previously used as replacement fluid in large PE trials, 
quintessentially with the same volume (half the volume 
of replacement fluid) we used in SVPE.4 5 SVPE-treated 
patients with GBS received approximately half the amount 
of IgG from the FFP used as replacement fluid compared 
with the total IVIg doses traditionally used in GBS (2 g/
kg). Third, FFP contains all human plasma proteins that 
help preservation of plasma colloid osmotic pressure and 
prevents formation of oedema and hypotension. Lastly, FFP 
is much cheaper than commercial human albumin.
In each day, three units of FFP were transfused as 
replacement fluid after the last session of SVPE and in 
the initial two to three sessions, normal saline was used 
as replacement fluid. This was done to achieve the 
maximum immunotherapeutic effect of FFP as SVPE 
was not resumed before the next day and the IgG in FFP 
remained in the circulation overnight for a longer period 
of time (10–12 hours). However, due to long half life of 
IgG, a substantial amount of IgG present in FFP was prob-
ably washed away due to repeated plasma removal both 
during SVPE and by conducting standard PE.
In GBS, treatment with modified methods of PE done 
previously, were device based and done on limited 
number of patients with GBS. In one study on 25 patients 
with GBS from India, daily removal of small volume of 
plasma (10–15 mL plasma/kg body weight) for dura-
tion of median 3 days using traditional PE machine was 
shown to be clinically beneficial.38 In another study from 
the same country, 12 patients with GBS were treated with 
PE over 10 days using different PE-machine kit (REF627 
kit from Haemonetics on MCS+machine) where authors 
claimed clinical improvement, however, the main focus 
was on cost-effectiveness and the total plasma volume 
exchanged per patient was not mentioned.39 Neverthe-
less, these methods are based on specific devices those 
are not in common practice, nor the trained personnel 
for these are available in the low-income and middle-in-
come countries.
Important observations in terms of secondary endpoints 
were transient hypotension, transfusion reaction to FFP 
and minor bleeding through the CVC insertion site. Hypo-
tension is a common complication during traditional PE 
that affects nearly half of patients.5 Spells of hypotension 
during SVPE were more frequent during the 3–4 days 
after initiation of SVPE, and could be easily corrected by 
rapid infusion of 300–400 mL saline (figure 1). The hypo-
tension could possibly be explained by hypovolaemia 
due to drawing blood or as a result of the compromised 
autonomic nervous system in patients with GBS. As SVPE 
proceeded, hypotensive spells were encountered less 
frequently despite drawing the same volume of blood, 
which may in part be explained by adaptation of the 
vasomotor system or recovery from autonomic dysfunc-
tion. Minor bleeding through the CVC insertion site 
occurred in 50% of patients and could be controlled by 
applying a simple pressure pack over the CVC insertion 
site in most cases; mild prolonged PT was noted in 30% 
(3/10) patients. However, spontaneous bleeding usually 
occurs if the PT is more than 2.5 times prolonged and PC 
is <0.50 lac/μL.40 Movement of the limb where the CVC 
was placed may have caused traction on the CVC and 
contributed to local bleeding in the other seven patients. 
Haematuria is not uncommon in patients with a UTI, as 
may have occurred in one SVPE-treated patient; traumatic 
traction of the urinary catheter may cause haematuria 
in two other catheterized SVPE-treated patient taking 
oral aspirin, who had haematuria and sterile urine. We 
also monitored the major organ function and biochem-
ical status of the patients treated with SVPE. No patients 
experienced hepatic or renal impairment. One patient 
developed anaemia and hypoalbuminaemia; this patient 
had severe sepsis, a common cause of anaemia and hypo-
albuminaemia in critically ill patients admitted to an 
ICU (patient 11, figure 1). Electrolyte imbalances were 
detected in 15% of the SVPE-treated patients with GBS, 
and were mild, subclinical and easily corrected.
The median reported durations to recovery of inde-
pendent walking in patients with GBS in large-scale RCTs 
after PE are 53, 52 and 70 days4 5 7; compared with 30 days 
in our patients treated with SVPE. Moreover, 60% of the 
patients with GBS treated with SVPE were able to walk 
independently at 4 weeks, whereas 20% of patients with 
GBS acquired independent walking ability at 4 weeks after 
traditional PE. However, these differences may possibly 
be due to the small sample size and variations in demo-
graphic and neurophysiological characteristics between 
cohorts. Finally, SVPE was completed in all 20 patients 
and no patients died.
limitations of sVPe
SVPE is a time-consuming and labour-intensive 
procedure, which is a limitation. We used multiple 
thin-lumen tubing systems interconnected with a multi-
channel connector device, which may increase the 
chance of blood coagulating within the tubing system. 
Coagulation may require manipulation or replacement 
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of the tubing to ensure free flow of blood and saline. 
Such handling could increase the chance of microbial 
contamination. A single continuous wide-lumen tubing 
system (SVPE kit) could resolve this problem. Most 
importantly, personnel conducting the SVPE procedure 
should maintain proper aseptic technique, which can 
sometimes be challenging in low-income and middle-in-
come countries. Furthermore, other adaptations 
such as provision of a larger blood bag or increasing 
the number of days for SVPE could be considered to 
increase the PE rate.
Clinical implications and future research
Despite the limitations, our study showed that SVPE is a 
safe and feasible treatment for GBS in a resource-limited 
setting where IVIg or PE is either unavailable or unaf-
fordable. Specifically, the poorest 20% of the world’s 
population (1.8 billion people) who typically earn less 
than US$10 per day and who are not covered by a 
national health insurance system may benefit. Consid-
ering the incidence of GBS is 2/100 000 in low-income 
and middle-income countries, approximately 40 000 
patients could potentially benefit from SVPE every year, 
worldwide. In the future, a multicentre RCT is required 
to assess the clinical efficacy of SVPE for patients with 
GBS. If proven effective, SVPE could be an affordable 
and easily available alternative PE technique in low-in-
come countries for patients with GBS and other disor-
ders, who at present cannot afford standard PE due to 
its high cost and unavailability.
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